INTRODUCTION
Despite progress in leukemia therapy, most adult patients still die from their disease. For patients with primary refractory acute myeloid leukemia (AML), or for those with relapsed disease, only 10% of patients will achieve long-term disease free survival. 1, 2 The prognosis for advanced acute lymphoblastic leukemia (ALL) is also poor. Patients with imatinib refractory or intolerant chronic myelogenous leukemia (CML) who enter blastic phase have a median survival of 3-9 months with current available therapies. Given these observations, new therapies are urgently needed.
The Aurora family of serine/threonine kinases is essential for mitotic progression. 3 Aurora-A has a critical role in mitotic spindle formation and centrosome maturation, ensuring faithful segregation of chromosomes into daughter cells. 4 In mammalian cells, abrogation of Aurora-A kinase activity disrupts cell cycle progression. Aurora-B is a chromosomal passenger protein essential for chromosomal congression and cytokinesis. 5 It is associated with centromeres during prometaphase and with the spindle midzone during anaphase and telophase. The function of Aurora-C remains unclear; however, in normal tissues, the expression of Aurora-C kinase is predominantly restricted to germ cells. 6 Expression and activity of the Aurora kinases (AKs) are tightly cell cycle regulated. Activity of all three proteins peaks during the G 2 and mitotic phases of the cell cycle, whereas expression is low or undetectable in resting cells. A variety of Aurora substrates have been identified, the best characterized being histone H3, a protein involved in chromosome condensation and mitotic entry.
The mammalian Aurora kinase family has been closely linked to tumorigenesis. 7 The most compelling evidence for this is that overexpression of Aurora-A transforms rodent fibroblasts. 8 Cells with elevated levels of this kinase rapidly become aneuploid and the oncogenic activity of AK is likely to be linked to the generation of such genetic instability. A correlation between amplification of the Aurora-A locus and chromosomal instability in mammary and gastric tumors has been observed. 9, 10 Furthermore, cellular overexpression of Aurora-A readily leads to the formation of tumors in nude mice. AK are overexpressed in a wide range of human tumors.
11 Aurora-B is highly expressed in multiple human tumor cells and levels increase as a function of stage in primary colorectal cancers. 12 Based on the known function of the AK, inhibitors of these enzymes would be expected to disrupt the cell cycle, inhibit proliferation and thus potentially reduce tumor growth.
MK-0457 is a small molecule kinase inhibitor of Aurora A, B and C that disrupts mitosis and induces apoptosis in cycling cells and has potent preclinical efficacy in a broad spectrum of leukemias, lymphomas and solid tumors. [13] [14] [15] [16] [17] In primary blast samples from patients with refractory AML, MK-0457 has significant activity with high potency (IC50 B60 nM). While MK-0457 is also a potent FLT-3 inhibitor (Ki 30 nM), anti-proliferative activity on AML cell lines appears to be FLT-3-independent. Moreover, cell cycle analysis shows that AML cells exposed to MK-0457 have an AK-inhibited phenotype with G 2 /M arrest and aneuploidy, rather than an FLT-3-inhibited phenotype with G 0 /G 1 arrest. In HL-60 human leukemia xenograft mouse models, 13 days of treatment caused significant tumor reduction relative to positive control at dose levels associated with neutropenia. Similarly, treatment of Ba/F3 FLT-3 ITD murine models of systemic AML with MK-0457 resulted in significantly longer survival times (and undetectable residual disease) compared with positive controls. MK-0457 is also a moderate to strong inhibitor of other kinases, which are targets relevant for a range of myeloproliferative disorders. MK-0457 inhibits the activity of ABL (Ki B30 nM), including T315I-mutated ABL (Ki, B42 nM), a highly resistant mutation that represents a significant current therapeutic challenge with no approved therapy. MK-0457 inhibits the proliferation of BaF3 cells harboring the ABL T315I mutation with an IC50 of B100 nM. MK-0457 inhibits the autophosphorylation of wild-type ABL with an IC50 of 360 nM. The combined activity of MK-0457 against the AK family and ABL, including the imatinib-resistant T315I ABL mutant, suggests potential opportunities for MK-0457 activity in imatinib-resistant CML. 18 MK-0457 also inhibits JAK-2 (Ki B190 nM), and inhibits viability of a JAK2 V617F mutant human erythroleukemia cell line with an IC50 of 17 mM. In addition, MK-0457 inhibited JAK-2-dependent STAT-5 activation with an IC50 of 4.6 mM in the JAK2 V617F mutant human erythroleukemia cell line. Therefore, MK-0457 may be of benefit in the treatment of JAK2-dependent myeloproliferative neoplasms. Based on the encouraging clinical and preclinical data for MK0457, we conducted a phase 1/II dose escalation study in patients with refractory hematological malignancies.
PATIENTS AND METHODS

Study design
This was an open-label phase I/II, non-randomized three-part study in patients with refractory hematologic malignancies with starting doses based on data from a study of MK-0457 in patients with refractory solid tumors, in whom myelosuppression was the dominant adverse event. 19 Phase I, part 1 of the study was a dose escalation study to establish the maximum tolerated dose (MTD) for a 5-day continuous IV infusion. Phase I, part 2 was a dose escalation to sequentially establish the MTDs for shorter duration infusions of 24 and 6 h. The phase II study comprised a cohort expansion at or below the MTD dose level. Expansion of the Phase II cohort was performed in order to collect additional biological information at clinically relevant doses. This patient population was enriched for AML and myeloproliferative neoplasm only. The protocol and study documents were approved by the appropriate Institutional Review Board or Ethics Committees. The study procedures adhered to applicable regulatory requirements, Good Clinical Practice and the Declaration of Helsinki. Written informed consent was obtained from all patients before any study specific procedure was performed. The study was registered at ClinicalTrials.Gov as NCT00111683.
Patient eligibility criteria
Patients with advanced myelodysplasia, acute leukemia, JAK2-expressing myelofibrosis and BCR-ABL T315I-mutated CML were eligible for the phase 1 portion of the study. Only patients with FLT3-mutated AML and JAK2 mutation-positive myeloproliferative neoplasm qualified for the phase 2 portion. Additional eligibility criteria included: age of at least 18 years; Eastern Cooperative Oncology Group (ECOG) performance status of p2; adequate renal function (creatinine within normal institutional limits or creatinine p2 mg/dl); adequate liver function (bilirubin p1.5 mg/dl and aspartate transaminase/alanine aminotransferase p3 times upper limit of normal). Patients were excluded for: treatment with an antileukemic investigational agent received within 14 days before entering study; documented history of allergic reactions attributed to compounds of similar chemical or biological composition to MK0457 or allopurinol; pregnancy or breastfeeding; uncontrolled intercurrent illness and known infection with HIV and/or viral hepatitis B or C.
Study assessments
Patient demographics and medical history were recorded at baseline. AE, physical examination, vital signs and ECOG performance status were assessed at baseline and every 2 weeks for the duration of the trial. Toxicity was graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0). Neurologic assessment was performed at baseline and repeated as clinically indicated. Hematology and clinical chemistries was carried out on days 1, 8 and 15 of every cycle. Patients remained on study until they no longer experienced clinical benefit, had progressive disease according to the investigator or experienced unacceptable toxicity. Patients were assessed for efficacy at the end of each 14-or 21-day cycle of therapy, ± 3 days according to published standard response criteria ('return to chronic phase' was applied to any patient who entered the study in an accelerated or blastic phase disease that then went on to meet the criteria for chronic phase following treatment).
Study treatment and dose escalation
For phase I, part 1, the initial dose level was set at 2 mg/m 2 /h repeated every 21 days. The dose for new cohorts was escalated as follows : 4, 8, 12, 16, 20, 24, 28, 32, 40 , 50 and 63 mg/m 2 /h. Dose escalation was continued until the MTD was achieved. Phase I, part 2 was designed to sequentially determine the MTDs for a 24-h continuous intravenous (CIV) infusion and 6-h IV infusion. The 24-and 6-h continuous infusions were given weekly for 3 weeks followed by a 1-week rest between cycles. The initial starting dose for the 24-h infusion was 64 mg/m 2 /h. This dose was increased by 50% until the MTD for the 24-h infusion was established. When the MTD for the 24-h infusion was established, dose escalation for a 6-h infusion was started in a new cohort of patients. The starting dose for the 6-h infusion was set at 150% of the MTD for the 24-h infusion. Dose escalation was continued in increments of 50% until the MTD for the 6-h infusion was established.
The dose escalation schema was broadly based on a '3 þ 3' design where dose escalation terminated when two (or more) of six patients experienced a dose limiting toxicity (DLT) in the same dose level. The next lower dose level would be the MTD if one DLT was observed in a cohort of six patients at that lower dose level. If that lower dose level only had three previously treated patients without DLT, then de-escalation to an intermediate dose halfway between that at which two patients had a DLT could take place. Alternatively, if an intermediate dose could not provide a pharmacokinetic advantage over the lower dose, then three additional patients would be added to the lower dose to complete a cohort of six patients. Establishing the MTD would require six patients and could not include more than one patient with a DLT.
Pharmacokinetic studies Samples were obtained from CML patients to quantify MK-0457 and potential metabolites in blood and urine. For phase I, part 1, blood samples were obtained at pre-dose, 0.5, 1.5, 4, 6, 24, 48, 72 and 96 h post start of infusion and again directly at the end of the infusion. For phase I, part 2, blood samples for the 24-h infusion were collected at predose (0), and 0.5, 1.5, 4, 6 and 24 h after the start of the infusion. For the 6-h infusion blood samples were collected at predose (0), and 3 and 6 h after the start of the infusion. Additional blood was drawn at 20 min, 40 min, 1, 2, 4, 6, 24 and 48 h post end of each of the 3 infusion regimes. In phase II, cycle 1 of the study, blood draws were obtained at three time points: at 48 h post start of infusion, either 72 or 96 h post start of infusion and at end of the 5-day infusion. Urine was collected for 24 h on day 1 and day 5 on the phase I, part 1 portion of the study.
Pharmacodynamic studies
Before dosing, peripheral blood and bone marrow aspirate was obtained for biomarkers that might correlate with clinical response to MK-0457. Blood PD marker assessments were repeated on day 5 of the first cycle. Preinfusion and day 5 blood samples were obtained in any individual patient who got dose escalated.
RESULTS
Seventy-seven patients whose pertinent demographic features are listed in Table 1 were enrolled on study. The average number of cycles per patient was 3 (range 1-21). The 24 mg/m 2 /h and 40 mg/ m 2 /h doses given as 5 day CIV were the most commonly administered regimens, with patients getting an average of 4.9 cycles (range: 1-11, mean treatment duration: 113.1 days) and 2.35 cycles (range: 1-11, mean treatment duration: 51.05 days), respectively.
In patients receiving the 5-day CIV regimen, the MTD was determined to be 40 mg/m 2 /h. In patients receiving the 24-h CIV regimen, the MTD was determined to be at least 144 mg/m 2 /h. The 6-h infusion regimen was not tested. Cytopenias were observed in 57.1% of patients. Febrile neutropenia was the most common toxicity seen (40.3%). Anemia and thrombocytopenia (all grades) were reported in 18.2% and 10.4% of patients, respectively.
Infections were the most commonly observed extramedullary AEs (Table 2) . Pneumonia was the most common infection seen (31%), followed by cellulitis (7.8%), oral candidiasis (6.5%) and bacteremia (5.2%). Gastrointestinal AEs were also common but were very rarely 3-5 events (Table 2 ). Of these, diarrhea (33.8%), nausea (31.2%), vomiting (18.2%), constipation (19.5%), stomatitis (13%) and abdominal pain (9.1%) were the most frequent. A pattern of pharyngolaryngeal pain (10.4%), Grade 3 in one patient (1.3%) with normal appearing oral mucosa was noted and was distinct from overt oral mucositis and/or oral candidiasis. There were 12 deaths on study (10 on the 5-day CIV regimen, 2 on the 24-h CIV regimen), the principal cause being disease progression-none were drug-related.
Pharmacokinetics
Pharmacokinetic data is summarized in Table 3 . At the dosage levels tested, the drug produced a dose-dependent increase in the area under the curve. Clearance was consistent across all dose levels and the half-life of the drug was between 13.7 and 16.7 h. Plasma concentrations achieved at end of infusion correlated with levels required for biological activity as predicted from preclinical models.
Pharmacodynamics
Given the responses observed in the CML patients on study (Table 4) , biomarkers predictive of BCR-ABL or AK inhibition in vivo were selected for analysis (phospho-CRKL, phospho-histone H3 and phospho-p53). The calculated phospho-CRKL/total-CRKL ratios pre-dose and at the end of infusion were obtained and the percentage change in these parameters was calculated. The same approach was taken with the other two biomarkers. No consistent correlation between changes in biomarker activity and response was demonstrable.
Efficacy
In a total of 18 patients with CML, 8 (44.4%) responses were observed. Seven returned to chronic phase at doses below the MTD for the 5-day CIV regimen-these responses were durable with patients receiving a range of 3-16 þ cycles of therapy. A patient with lymphoid blastic phase disease had a complete response at the MTD for the same regimen. All these patients had clinically progressive CML with the highly tyrosine kinase inhibitor-resistant BCR-ABL T315I mutation phenotype (Table 4) . In a total of 38 patients with AML accrued, no complete responses were observed. No responses were observed either in patients with Ph-positive ALL or in the patients with myelofibrosis. DISCUSSION MK-0457 is a small-molecule pan AK inhibitor with potent preclinical activity across a broad range of neoplasms including xenograft models of leukemia. Data from a phase I 20 study in patients with refractory solid tumors where MK-0457 was given over 5 days as a continuous intravenous infusion every 28 days Abbreviations: AUC, area under the curve; CEOI, concentration at end of infusion; Cmax, maximum plasma concentration; CML, chronic myelogenous leukemia; T1/2, half life. Although every effort was made to collect samples according to the protocol, dosing noncompliance, dose adjustments and technical issues account for the obvious outliers in this analysis.,
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has been reported. The MTD for this regimen was 10 mg/m 2 /h, and two patients on this study (one with pancreatic cancer and the other with lung cancer) achieved stable disease. Myelosuppression was the most important toxicity observed.
In the current study, the responses observed in patients that had BCR-ABL T315I mutations are noteworthy. This mutation affects a common ABL kinase contact residue leading to treatment failures and high-level cross-resistance to currently approved ABL kinase inhibitors. 21 Survival largely depends on the phase of disease at the time the mutation is discovered and whether or not stem cell transplantation is available as the most established therapeutic option. Several novel compounds are being evaluated to deal with this highly resistant point mutation; however, few have proven efficacy and tolerability in the clinic. Of these, the multi-targeted kinase inhibitor ponatinib (Ariad Pharmaceuticals, Cambridge, MA, USA) appears to hold the most promise and is currently in pivotal trials. In this phase I/II study, we report a large number of patients with BCR-ABL T315I mutations that responded to a small molecule inhibitor. MK-0457 binding with its target accommodates the substitution of isoleucine for threonine at ABL residue 315 based on crystallographic studies 21 and explains the important clinical activity that we observed. By comparison to ponatinib and other similarly targeted agents, one of the limitations of MK-0457 was the requirement to deliver therapy as a continuous infusion, which is a disadvantage relative to oral therapies if chronic uninterrupted treatment to maintain suppression of T315I clones is necessary. A potential advantage of MK-0457 over ponatinib may be that additional AK inhibitor activity may produce more myelosuppression than may be observed with a specific BCR-ABL inhibitor, which has the advantage of being able to manage/control very aggressive blastic phase disease. MK-01457 may represent an important therapeutic 'bridge' to stem cell transplantation in selected patients. This very well tolerated agent has clinical activity in patients with a major unmet need 22 and merits further clinical development.
Recent reports have indicated that combinations of other targeted agents with MK-0457 merit clinical exploration. Kretzner et al. 23 have reported on the growth and survival of multiple lymphoma cell lines exposed to MK-0457 in combination with vorinostat, a histone deacetylase inhibitor HDACi. The addition of vorinostat reactivated proapoptotic genes and enhanced lymphoma cell death by epigenetic and protein acetylation mechanisms. Okabe et al. 24 have reported similar synergistic induction of apoptosis by the combination of vorinostat and MK-0457 in primary BCR-ABL T315I-positive ALL. Nguyen et al. 25 have also documented a similar synergy between vorinostat and the dual BCR-ABL/AKI KW-2449 in CML including those with the T315I or E255K imatinib-resistant phenotype.
Gizatullin et al. 26 investigated the role of p53 and p21 (Waf1/Cip1) in cell cycle changes induced by MK-0457. Endoreduplication and apoptosis in response to drug exposure was limited in some, but not all, cells expressing wild-type p53, and markedly enhanced in cells lacking p53. The difference in response to MK-0457 among cell lines correlated with the timing of induction of p21 (Waf1/Cip1) and its ability to inhibit cyclin E-cdk2 activity. These data suggest that the integrity of the p53-p21 (Waf1/Cip1)-dependent postmitotic checkpoint is crucial to MK-0457 activity. Although cells with intact checkpoint function arrest with 4N DNA content, those with compromised checkpoint function are more likely to undergo endoreduplication followed by eventual apoptosis. The combination of MK-0457 with agents that modulate checkpoint function would be particularly interesting. An intriguing possibility is the combination, suggested by Cheok et al., 27 of MK-0457 with agents (for example, nulin-like inhibitors) that, by non-genotoxic activation of p53, cause a reversible activation of G 1 and G 2 arrest in normal cells, thus preventing these cells from entering mitosis. This latter effect may protect from MK-0457 adverse effects. Kojima et al. 28 have also reported the synergistic effect of MK-0457, and a selective smallmolecule antagonist of Mdm2, Nutlin-3, in inducing p53, conformational change of Bax and Deltapsi(m) loss, suggesting an involvement of p53-mediated mitochondrial apoptosis. Nutlin-3 constrained endoreduplication after Aurora inhibition via activation of a p53-dependent postmitotic checkpoint and p21 induction in pseudo-G 1 cells.
Intriguing questions remain about the mode of action of AKI in specific hematologic malignancies. We observed no significant anti-AML activity of MK-0457, which potently inhibits AK A and B, 15 yet Lowenberg et al. 29 and Tsuboi et al. 30 have both recently documented significant clinical activity of barasertib (AZD1152) in patients with refractory AML. The latter is a relatively specific and potent inhibitor of AK B. Donato et al. 31 have reported that MK-0457 apoptotic activity in CML cells is primarily associated with AKI but can be affected by multiple molecular changes associated with leukemia progression and/or acquisition of imatinib resistance. Fei et al. 32 have reported that MK-0457 has significant activity against primary human Ph-positive ALL cells both with and without the T315I mutation, including ablation of tyrosine phosphorylation downstream of BCR-ABL, decreased viability and induction of apoptosis. However, drug treatment of human Ph-positive ALL cells for 3 days followed by drug removal allowed the outgrowth of abnormal cells 21 days later, and on culture of mouse BCR-ABL þ ALL cells on stroma with lower concentrations of MK-0457, drug-resistant cells emerged. Combined treatment of human ALL cells lacking the T315I mutation with both MK-0457 and dasatinib was associated with significantly more cytotoxicity than with each agent alone. The authors advocate the study of a combination of MK-0457 with a second BCR-ABL inhibitor in patients with T315I Ph-positive ALL. We have recently reported synergy between an AK A inhibitor, MLN8237, which has no BCR-ABL inhibitory activity, and nilotinib, a selective potent BCR-ABL inhibitor, in a range of preclinical models of imatinib-resistant CML. 33 Combinations of MK-0457 with the agents highlighted in these reports would be of particular interest. 34, 35 MK-0457 in BCR-ABL T315I leukemia FJ Giles et al
